BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Phase 3 PEGASUS trial evaluating PALYNZIQ® (pegvaliase-pqpz) met its primary efficacy endpoint, demonstrating a statistically ...

A Phase 2 clinical trial finds that ALT flares are common in hepatitis D patients treated with pegylated interferon-alpha, ...

Brii Biosciences has reported promising interim results from its Phase II ENSURE study of elebsiran, a hepatitis B ...

The global interferons market is on a steady growth trajectory, with its valuation projected to surge from USD 9.4 billion in 2022 to USD 13.8 billion by 2032. According to a recent report by Future ...